Drugs / PF614
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06500793 | Nov 2024 → Dec 2026 expected | — | Ensysce Biosciences | Recruiting | No outcome recorded |
| Phase 1 | NCT05571345 | Oct → Dec 2022 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05567354 | Jun → Aug 2022 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05090280 | Dec 2021 → Apr 2023 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05043766 | Sep 2021 → Mar 2022 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02454712 | Nov 2016 → Jan 2018 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06629402 | Oct → Nov 2023 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06602271 | Dec 2025 → Aug 2026 overdue | — | Ensysce Biosciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF614 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02454712 ↗ |
| Route | Oral | “Subjects will receive PF614 (n=6) or OxyContin as comparator (n=2) orally in the fasted state.” NCT02454712 ↗ |